Minyahil A. Woldu
Pharmacotherapy Dermatology Life Quality Index HIV/AIDS drug development and treatment Blood Pressure and Hypertension Studies Medication therapy management Multicenter AIDS Cohort Study Cross-sectional study Human immunodeficiency virus (HIV) Targeted drug delivery Antiretroviral therapy Antiretroviral drug Epilepsy research and treatment Diabetes, Cardiovascular Risks, and Lipoproteins Skin Diseases and Diabetes Drug Resistant Epilepsy Hospital-acquired infection Hospital-acquired pneumonia Antibiotic Use and Resistance Antibiotic resistance Antibiotic Resistance in Bacteria Quality of Life Research Applied Microbiology and Biotechnology Cardiology and Cardiovascular Medicine Complementary and alternative medicine Dermatology Endocrinology, Diabetes and Metabolism Infectious Diseases Molecular Medicine Psychiatry and Mental health

Educational Journey

Muhimbili University of Health and Allied Sciences

PhD in Hospital and Clinical Pharmacy in Clinical Pharmacy and pharmacology • Clinical Pharmacy and pharmacology

2023

HDP

Higher Diploma in Pedagogy • Pedagogy

2016

Jimma University

MSc in Pharmacy • Pharmacy

2012
Show all 4 education

Experience

Clinical Pharmacy Coordinator

2023 - Present

Postgraduate Program Coordinator of Clinical Pharmacy

2022 - 2023

Assistant Professor

2017 - Present
Show all 9 experience

Editors Role

Reviewer

GJMR

0 -

Affiliations

International Association of Public Health Logisticians (IAPHL)

Membership

Member since 2017

Society for AIDS in Africa

Membership

Member since 2016

International AIDS Society

Membership

Member since 2016
Show all 4 affiliations

Advisors

Tesfa Marew

Mentor

Mekelle General Hospital

Grants and Awards

GRANT

Cardiometabolic syndrome in HIV-positive and HIV-negative patients at Zewditu Memorial Hospital, Addis Ababa, Ethiopia: an observational comparative cohort study

DAAD

2017
GRANT

Assessment of drug therapy management provided to patients with chronic illnesses attending follow up clinics of Tikur Anbessa specialized hospital, Addis Ababa: an interventional study

Addis Ababa University

2016

Research

Design and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor

Article May 7, 2014

Malignant brain tumours are one of the most devastating human cancers associated with high mortality and morbidity rates. The median survival of malignant glioma patients ranges between 3 and 16 months and has virtually remained unchanged during the last 3 decades. Difficulties in early detection, local recurrence, and resistance to conventional therapies are the major reasons for failure in malignant brain tumour treatment. The therapy of malignant gliomas is further limited by the inadequate delivery of therapeutic agents to the brain due to the presence of the blood-brain barrier, blood– brain–tumor barrier as well as non-specificity targeting. Nanoparticles (NPs) have drawn increased interest in treating malignant brain tumours due to their potential to act as a vector for brain delivery and to provide tumour-specific detection and treatment. If designed appropriately, NPs may act as a drug vehicle able to target tumor tissues or cells, and protect the drug from inactivation during its transport. The aim of this article was to provide brief overview of nanoparticulate drug delivery systems for imaging and treatment of brain cancer and to evaluate their safety in clinical use. Besides invasive physical methods to bypass or disrupt the BBB and/or BBTB, other methods like pharmacological and physiologic approach are possible. Different manufacturing methods of nano-formulation have been investigated and these include nano-precipitation, emulsion polymerization, emulsion solvent evaporation, supercritical fluid expansion method, complex coacervation, salting out method, and denaturation. liposomes can serve as a controlled release carrier or simply as a biocompatible solubilizing vehicle for poorly soluble agents. Dendrimers are organic NPs capable of crossing the BBB to deliver therapeutics to tumors. Most inorganic NPs employ an organic polymer as a protective layer so as to increase circulation, half-life and to protect both the particle from the body and the